Skip to main content

Amphotericin B Liposomal Dosage

Medically reviewed by Drugs.com. Last updated on Feb 16, 2023.

Applies to the following strengths: 50 mg

Usual Adult Dose for Aspergillosis - Invasive

3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Candidemia

3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Cryptococcosis

3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Adult Dose for Febrile Neutropenia

3 mg/kg/day IV over 120 minutes

Comments:


Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.

Usual Adult Dose for Cryptococcal Meningitis - Immunosuppressed Host

6 mg/kg/day IV over 120 minutes

Comments:


Use: Treatment of Cryptococcal meningitis in HIV infected patients

Usual Adult Dose for Leishmaniasis

Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21


Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38

Comments:

Use: Treatment of visceral leishmaniasis

Usual Adult Dose for Coccidioidomycosis

Severe, non-meningeal infection: 3 to 5 mg/kg/day IV
Duration of therapy: Until clinical improvement


Use: Coccidioidomycosis

Usual Adult Dose for Blastomycosis

Moderate to severe pulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted


Moderate to severe extrapulmonary blastomycosis: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted

CNS blastomycosis: 5 mg/kg/day IV
Duration of therapy: 4 to 6 weeks

Blastomycosis, immunosuppressed patient: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted

Blastomycosis during pregnancy: 3 to 5 mg/kg/day IV
Duration of therapy: 1 to 2 weeks or until improvement is noted


Use: Blastomycosis

Usual Pediatric Dose for Aspergillosis - Invasive

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Candidemia

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Cryptococcosis

1 month and older:
3 to 5 mg/kg/day IV over 120 minutes

Comments:


Uses: Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or where renal impairment or toxicity precludes use of amphotericin B deoxycholate.

Usual Pediatric Dose for Febrile Neutropenia

1 month or older:
3 mg/kg/day IV over 120 minutes

Comments:


Use: Empiric therapy for presumed fungal infection in febrile, neutropenic patients.

Usual Pediatric Dose for Cryptococcal Meningitis - Immunosuppressed Host

1 month or older:
6 mg/kg/day IV over 120 minutes

Comments:


Use: Treatment of Cryptococcal meningitis in HIV infected patients

Usual Pediatric Dose for Leishmaniasis

1 month or older:
Immunocompetent patients: 3 mg/kg/day IV on days 1 through 5, and days 14 and 21


Immunocompromised patients: 4 mg/kg/day IV on days 1 through 5, and days 10, 17, 24, 31 and 38

Comments:

Use: Treatment of visceral leishmaniasis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 1 month.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:


IV compatibility:

General:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.